Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
News|Articles|October 1, 2026
7 Cardiology Headlines You Missed in September 2026
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Advertisement
Advertisement
After a packed August, September 2026 was a comparatively quiet month for cardiology. However, despite having less in the way of major conferences and trial readouts, this past month made up for it with several major decisions from the
Related to this article
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Advertisement
Advertisement